Rabbit anti-thymocyte globulin clinical trials
Rabbit anti-thymocyte globulin is named as an intervention in 3 current clinical trials in our USA, France, Spain, Brazil, UK, China, Italy, Netherlands, Belgium, Sweden, Denmark, Czechia, Australia and Israel registers. 3 are recruiting patients now. The most common phase is Phase 2/3. The sponsor with the most trials is Sanofi (1). The most-studied condition is Kidney Transplant Rejection.
Patient leaflets for Rabbit anti-thymocyte globulin
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Rabbit anti-thymocyte globulin
3 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Induction in Sensitized Kidney Transplant Recipients Without Pre-existing Donor-specific antiboDies
NCT05385432 · ClinicalTrials.gov ↗ · Renal Transplant Rejection, Induction Therapy
|
Phase 3 | Recruiting | University Hospital, Tours | France |
|
A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation
NCT07412470 · Kidney Transplant Rejection
|
Phase 2/3 | Recruiting | Sanofi | UK, USA, China, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Czechia, Brazil, Australia, Israel |
|
A Study Comparing Siplizumab With Rabbit Anti-Thymocyte Globulin to Help the Body Accept a Kidney Transplant
NCT07508787 · Renal Transplant Failure and Rejection
|
Phase 2 | Recruiting | Nefro Avillion Clinical Development, LLC | USA, Spain, Brazil |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Rabbit anti-thymocyte globulin
4 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Sanofi | 1 |
| Nefro Avillion Clinical Development, LLC | 1 |
| University Hospital, Tours | 1 |
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Rabbit anti-thymocyte globulin trials
How many clinical trials are testing Rabbit anti-thymocyte globulin?
3 current trials in our USA, France, Spain, Brazil, UK, China, Italy, Netherlands, Belgium, Sweden, Denmark, Czechia, Australia and Israel registers name Rabbit anti-thymocyte globulin as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Rabbit anti-thymocyte globulin trials recruiting patients?
Yes. 3 of the 3 trials are recruiting: 2 with sites in USA, 2 with sites in France, 2 with sites in Spain, 2 with sites in Brazil, 1 with sites in UK, 1 with sites in China, 1 with sites in Italy, 1 with sites in Netherlands, 1 with sites in Belgium, 1 with sites in Sweden, 1 with sites in Denmark, 1 with sites in Czechia, 1 with sites in Australia and 1 with sites in Israel. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Rabbit anti-thymocyte globulin clinical trials?
Sanofi (1), Nefro Avillion Clinical Development, LLC (1) and University Hospital, Tours (1). The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Rabbit anti-thymocyte globulin works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Rabbit anti-thymocyte globulin works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Rabbit anti-thymocyte globulin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.